DISEASE INDICATIONS:Psoriasis
MANUFACTURER:AbbVie Ltd
USAGE:Subcutaneous
MEDICINE APPROVED BY:
European Medical Agency (EMA)
Food and Drug Administration (FDA)
Therapeutic Goods Administration (TGA)
Skyrizi is a prescription medication that treats moderate to severe plaque psoriasis in adult patients by blocking a protein called interleukin-23.